Policy
Britain has world-class scientific institutions and a chronic inability to turn their outputs into commercial and industrial success. That is a political failure, and it has a political solution.
Marc has worked at the commercial end of British innovation. He has taken scientific discoveries from academic institutions through regulatory approval and into clinical and commercial use in the UK and US markets. He has navigated the MHRA, the FDA, NHS procurement, and US hospital systems. He knows where British innovation loses momentum, and it is almost always at the point of translation: the gap between a strong research base and a functioning market for the outputs of that research.
His view is that a credible Conservative industrial strategy must start with honesty about what the market alone will not deliver. Basic research, early clinical development, and the infrastructure for technology adoption in public services all require deliberate government intervention. The question is not whether the state plays a role but whether it plays it intelligently.
Marc is a supporter of the approach taken by ARIA and believes it should be expanded and protected. He wants to see a serious life sciences industrial strategy that treats the sector's export potential as a national priority, that aligns UKRI funding with commercial translation, and that makes Britain the most attractive regulatory environment in the world for companies developing genuinely innovative diagnostics and therapeutics.
He also believes the Conservative Party needs to make this argument more confidently, rather than ceding industrial strategy to Labour as though it were inherently a left-wing concept.